Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2024

D'Angelo Sandra P, Lebbé Céleste, Nghiem Paul, Brohl Andrew S, Mrowiec Thomas, Leslie Trent, Georges Sara, Güzel Gülseren, Shah Parantu

Abstract excerpt

PURPOSE: Avelumab (anti-PD-L1) became the first approved treatment for metastatic Merkel cell carcinoma (mMCC) based on results from the phase II JAVELIN Merkel 200 trial. In this study, we report exploratory biomarker analyses from the trial. PATIENTS AND METHODS: Patients with mMCC (n = 88) with or without prior first-line chemotherapy received avelumab 10 mg/kg every 2 weeks. We conducted analyses on somatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Carcinoma, Merkel Cell

Share to Exome Sequencing

Share to Skin Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39047170
DOI: 10.1158/1078-0432.CCR-23-0395
PMCID: PMC11443199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma.PMID 39047170Read ↗

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.Semantic proximity Read ↗

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.Semantic proximity Read ↗

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumorsSemantic proximity Read ↗

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy EfficacySemantic proximity Read ↗

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.Semantic proximity Read ↗

miRNAs driving diagnosis, prognosis and progression in Merkel cell carcinomaSemantic proximity Read ↗

Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilitiesSemantic proximity Read ↗

Evolving Applications of Circulating Tumor DNA in Merkel Cell CarcinomaSemantic proximity Read ↗

Delta-Like Protein 3 Expression and Targeting in Merkel Cell CarcinomaSemantic proximity Read ↗

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECSemantic proximity Read ↗

Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.Semantic proximity Read ↗

Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.